Fiche centre
Kindai University Hospital
Sakai — Japan
Essais liés5clinical trials
VilleSakailocalisation
PaysJapanlocalisation
SourcelocaleCSV/MySQL
Informations
centreSynchronisé depuis ClinicalTrials.gov — NCT07373353
Essais cliniques associés
5| Molécule | Indication / population | Phase | NCT | Titre | Statut |
|---|---|---|---|---|---|
| Pumitamig | Cancer | Phase 3 | NCT07173751 | ROSETTA Breast-01: The Effects and Safety of Pumitamig in Patients With Triple-Negative Breast Cancer | RECRUITING |
| Nivolumab | Cancer | Phase 3 | NCT06561386 | RELATIVITY1093 — A Study to Compare the Efficacy of Nivolumab and Relatlimab Plus Chemotherapy vs Pembrolizumab Plus Chemotherapy for Stage IV/Recurrent Non-squamous Non-small Cell Lung Cancer With PD-L1 Expression ≥ 1% | RECRUITING |
| AMJ-401 | Maladie coronarienne | Non applicable | NCT07373353 | A Clinical Evaluation of AMJ-401 | ACTIVE_NOT_RECRUITING |
| AQUA07 | Cancer | Phase 1 | NCT07617337 | AQUA07 in Patients With ALK-Positive Non-Small Cell Lung Cancer | RECRUITING |
| Tacabrutideg | Cancer | Phase 3 | NCT06846671 | CaDAnCe-302 — A Study of Tacabrutideg (BGB-16673) Compared to Investigator's Choice in Participants With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Previously Exposed to Both Bruton Tyrosine Kinase (BTK) and B-cell Leukemia/Lymphoma 2 Protein (BCL2) Inhibitors | RECRUITING |